This case report describes the medication-focused individualized application of existing precision tools for a patient with CSF1R gene mutation and leukodystrophy following allogeneic hematopoietic stem cell transplantation (allo-HSCT). The gene discussed is CSF1R; the disease is leukodystrophy.